Phase II trial of concurrent Nivolumab and radiation therapy in chemotherapy ineligible muscle invasive bladder cancer [NUTRA trial NCT03421652]

被引：0
|
作者：
George, Saby [2 ]
Heilbrun, Lance [1 ]
Maier, Jordan [3 ]
Dickow, Brenda [3 ]
Kuettel, Michael [2 ]
Frazier, Arthur [3 ]
Suisham, Stacey [3 ]
Parajuli, Prahlad [3 ]
Vaishampayan, Nitin [3 ]
Vaishampayan, Ulka [3 ]
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] Roswell Pk, Buffalo, NY USA
[3] Karmanos Canc Ctr, Detroit, MI USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O24
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]
    Vaishampayan, U. N.
    Heilbrun, L. K.
    Vaishampayan, N.
    Li, C.
    Shi, D.
    Frazier, A.
    Maier, J.
    Dickow, B.
    Kuettel, M.
    Chatta, G.
    George, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S596 - S596
  • [2] Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients
    Vaishampayan, Ulka N.
    Heilbrun, Lance
    Vaishampayan, Nitin
    Harper, Felicity W. K.
    Shi, Dongping
    Smith, Daryn
    Green, Kelly
    Guru, Khurshid
    Li, Qiang
    Kuettel, Michael
    Chatta, Gurkamal
    Maier, Jordan
    Dickow, Brenda
    Moore, Tanina Foster
    George, Saby
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1472 - 1480
  • [3] A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin ineligible muscle invasive bladder cancer
    Satkunasivam, R.
    Teh, B. S.
    Riveros, C.
    Lim, K.
    Wallis, C. J. D.
    Hu, S.
    Melchiode, Z.
    Nikolos, F.
    Miles, B. J.
    Kaushik, D.
    Chen, S. H.
    Efstathiou, E.
    Chan, K. S.
    Esnaola, N. F.
    Sonpavde, G. P.
    EUROPEAN UROLOGY, 2024, 85 : S415 - S415
  • [4] A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer (RAD VACCINE MIBC)
    Satkunasivam, Raj
    Lim, Kelvin
    Teh, Bin S.
    Esnaola, Nestor F.
    Slawin, Jeremy
    Zhang, Jun
    Miles, Brian
    Brooks, Michael Austin
    Anis, Maryam
    Muhammad, Taliah
    Farach, Andrew M.
    Chen, Shu-Hsia
    Efstathiou, Eleni
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer
    Magnino, A
    Gatti, M
    Massucco, P
    Sperti, E
    Faggiuolo, R
    Regge, D
    Capussotti, L
    Gabriele, P
    Aglietta, M
    ONCOLOGY, 2005, 68 (4-6) : 493 - 499
  • [6] A prospective phase II trial of neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of bladder.
    Kim, Hongsik
    Kim, Ryul
    Hong, Joohyun
    Kwon, Ghee Young
    Kim, Chan Kyo
    Park, Won
    Song, Wan
    Sung, Hyun Hwan
    Jeong, Byong Chang
    Hong, Jung Yong
    Park, Se Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [7] Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)
    Geynisman, Daniel M.
    Abbosh, Philip H.
    Ross, Eric
    Zibelman, Matthew R.
    Ghatalia, Pooja
    Anari, Fern
    Mark, James R.
    Stamatakis, Lambros
    Hoffman-Censits, Jean H.
    Viterbo, Rosalia
    Greenberg, Richard E.
    Churilla, Thomas M.
    Horwitz, Eric M.
    Hallman, Mark A.
    Smaldone, Marc C.
    Uzzo, Robert
    Chen, David Y. T.
    Kutikov, Alexander
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
  • [8] Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
    Li, Roger
    Villa, Nancy Y.
    Yu, Xiaoqing
    Johnson, Joseph O.
    Borjas, Gustavo
    Dhillon, Jasreman
    Moran-Segura, Carlos M.
    Kim, Youngchul
    Francis, Natasha
    Dorman, Denise
    Powers, John J.
    Sexton, Wade J.
    Spiess, Philippe E.
    Poch, Michael A.
    Zemp, Logan
    Gilbert, Scott M.
    Zhang, Jingsong
    Pow-Sang, Julio M.
    Anderson, Alexander R. A.
    Li, Tingyi
    Wang, Xuefeng
    Grass, G. Daniel
    Burke, James M.
    Dinney, Colin P. N.
    Rodriguez, Paulo C.
    Jain, Rohit K.
    Mule, James J.
    Conejo-Garcia, Jose R.
    NATURE MEDICINE, 2025, 31 (01) : 176 - 188
  • [9] Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough
    Winquist, Eric
    Booth, Christopher M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (24) : 2709 - +
  • [10] Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.
    Cuellar, M. Andres
    Medina, Ana
    Girones, Regina
    Valderrama, B. P.
    Font, Albert
    Juanfita, M. J.
    de Velasco, Guillermo
    Ferrer, Ferran
    Vigues, Francesc
    Garcia del Muro, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345